R. Houston Thompson, MD

home / authors / r-houston-thompson-md

Articles

Site Logo

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Simon P. Kim, MD, MPH;Cary P. Gross, MD;Quoc-Dien Trinh, MD;Marc C. Smaldone, MD, MSHP;R. Houston Thompson, MD;Sarah P. Psutka, MD;Holly Van Houten, BA;Leona C. Han, BA;Robert Abouassaly, MD
February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Read More

Latest Updated Articles

AHA Statement Reviews Benefits, Risks of Alternative Therapies for Heart Failure
Published: October 1st 2024 | Updated: October 3rd 2024
AHA Statement Reviews Benefits, Risks of Alternative Therapies for Heart Failure
Schizophrenia FDA Approval | Image Credit: Aquir - stock.adobe.com
Published: September 27th 2024 | Updated: October 3rd 2024
FDA Approves Cobenfy, Previously KarXT, for Treatment of Schizophrenia
PrEP Prescribing Patterns Reveal Disparities in HIV Prevention Across Settings
Published: September 26th 2024 | Updated: October 3rd 2024
PrEP Prescribing Patterns Reveal Disparities in HIV Prevention Across Settings
Case Study: Pharmacist Management of Inappropriate Prednisone Dosing Triggered By Asthma
Published: September 26th 2024 | Updated: October 3rd 2024
Case Study: Pharmacist Management of Inappropriate Prednisone Dosing Triggered By Asthma
Teclistamab Demonstrates Continued Deep, Durable Responses in Long-Term Follow-Up From MajesTEC-1 Trial
Published: September 27th 2024 | Updated: October 3rd 2024
Teclistamab Demonstrates Continued Deep, Durable Responses in Long-Term Follow-Up From MajesTEC-1 Trial
CEPHEUS Study Results Show Efficacy of Daratumumab-Based Quadruplet, Triplet Therapeutic Approaches
Published: September 27th 2024 | Updated: October 3rd 2024
CEPHEUS Study Results Show Efficacy of Daratumumab-Based Quadruplet, Triplet Therapeutic Approaches